EU/3/00/013
About
On 29 December 2000, orphan designation (EU/3/00/013) was granted by the European Commission to Laxdale Ltd., United Kingdom, for ethyl eicosopentaenoate for the treatment of Huntington's disease. The name of the sponsor has since changed to Amarin Neuroscience Ltd.
Key facts
Active substance |
Ethyl Eicosapentaenoate
|
Disease / condition |
Treatment of Huntington’s disease
|
Date of first decision |
29/12/2000
|
Outcome |
Positive
|
EU designation number |
EU/3/00/013
|
Sponsor's contact details
Amarin Neuroscience Ltd
Kings Park House
Laurelhill Business Park
STIRLING FK7 9JQ
United Kingdom
Telephone: +44 17 86 47 60 00
Telefax: +44 17 86 47 31 37
E-mail: admin@amarin-neuro.com
Kings Park House
Laurelhill Business Park
STIRLING FK7 9JQ
United Kingdom
Telephone: +44 17 86 47 60 00
Telefax: +44 17 86 47 31 37
E-mail: admin@amarin-neuro.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: